Industrial Layout / INDUSTRIAL LAYOUT

Industrial Layout




Fast track to the Chinese market

Experienced partners


        Ever since 2014, Dongcheng Pharmaceutical entered the nuclide drug industry with high technological barriers and growth potential, successively acquired Chengdu Yunke Pharmaceutical, Shanghai Yitai Pharmaceutical and GMS (China), and completed the company’s entire industry chain deployment from diagnostic nuclide drugs to therapeutic nuclide drugs. In 2017, Dongcheng Pharmaceutical acquires 100% of shares of Nanjing AMS Electronic Development Research Co., Ltd. This further consolidated the company’s leading position in the field of nuclide drugs in China and made it a leading enterprise that can provide the total nuclear medicine solution in the Chinese market.


      The nuclide drug sector of Dongcheng Pharmaceutical has subsidiaries or branches in dozens of cities throughout the country. It is dedicated to the production and sales, equipment supply, technology research and consulting, after-sales service of related products in the nuclear medicine field, and provides the all-around nuclear medicine solutions for medical institutions. Chengdu Yunke Pharmaceutical Co., Ltd. controlled by Dongcheng Pharmaceutical is the first enterprise in China that passes the GMP certification in the field of nuclear medicine, and its main product “Yunke Injection” is the first nuclide drug independently developed in China for the clinical therapy with RA and was awarded the national invention patent; Dongcheng GMS, the largest producer and distributor of SPECT drugs in China, owns iodine [125I] sealed seed source, a tumor brachytherapy product, and urea [14C] capsule, a product for clinical diagnosis of HP infection; Dongcheng AMS is the largest producer and distributor of PET drugs in China, and also a total solution provider of the most specialized cyclotron system in China. Shanghai Yitai Pharmaceutical has the only clinical stage IIb 1.1 therapeutic nuclide drug in China, rhenium [188Re] etidronate injection, for the treatment of malignant tumor bone metastases.MITRO Biotech Co., Ltd. is a molecular imaging contract research organization (MI-CRO) company in China. It’s Core technology of molecular imaging has outstanding advantages such as in vivo imaging, dynamic quantification, self-control, continuous observation, etc., which can help pharmaceutical enterprises greatly shorten the drug R & D cycle, reduce the risk of failure, and accelerate the listing of new drugs.


      Dongcheng Pharmaceutical, with the nuclide drug as the new core competitive power, constantly takes advantage of the capital market, concentrates the advantageous resources of the company, integrates the nuclide drug industry, and builds a full value chain industry platform of the nuclide drug with the development ideas of “setting foot in the upstream, integrating the downstream and deployment at the frontier”.





Add:No.7 ChangBaiShan Road, Yantai Development Zone, ShanDong, China
About Us
Company Profile
Chairman Address
Honors of Dongcheng
Evolutional History
Development Strategy
Corporate Culture
Contact Us
Group News
Media Coverage
API Series
Preparation Series
Nuclide Drug Series
Health Care Business
Technology Platform
Honors and Qualifications
Advanced Equipment
Talent Concepts
Talent Development
Talent Recruitment
Instant Quotes
Regular Reports
Investor Services
Social Welfare
Safety & Environmental Protection
Occupational Health
COPYRIGHT 2020 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All rights reserved 魯ICP備18035060號-1